These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 1977185)

  • 21. Aminosalicylates in the treatment of children with inflammatory bowel disease. Summary of the workshop on aminosalicylate pharmacology.
    Ferry GD
    Inflamm Bowel Dis; 1998 May; 4(2):113-4; discussion 114-6. PubMed ID: 9687218
    [No Abstract]   [Full Text] [Related]  

  • 22. Dipentum (olsalazine sodium).
    Swartz ML
    Gastroenterol Nurs; 1991 Dec; 14(3):144-7. PubMed ID: 1760451
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Aminosalicylates and steroids in the treatment ot chronic inflammatory bowel diseases--consensus paper of the Working Group for Chronic Inflammatory Bowel Diseases of the OGGH].
    Dejaco C; Haas T; Kirchgatterer A; Miehsler W; Wenzl H; Knoflach P; Petritsch W; Vogelsang H; Reinisch W; Tilg H
    Z Gastroenterol; 2006 Jun; 44(6):525-38; discussion 539. PubMed ID: 16773519
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Free radicals in inflammatory bowel diseases pathophysiology and therapeutic implications.
    Gross V; Arndt H; Andus T; Palitzsch KD; Schölmerich J
    Hepatogastroenterology; 1994 Aug; 41(4):320-7. PubMed ID: 7959565
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Safety of balsalazide therapy in the treatment of inflammatory bowel disease.
    Baker DE
    Rev Gastroenterol Disord; 2005; 5(3):135-41. PubMed ID: 16127348
    [TBL] [Abstract][Full Text] [Related]  

  • 26. 5-aminosalicylates in inflammatory bowel disease and chronic renal failure.
    Tekin F; Ozutemiz O; Ilter T
    Aliment Pharmacol Ther; 2005 Sep; 22(6):579; author reply 579-80. PubMed ID: 16167976
    [No Abstract]   [Full Text] [Related]  

  • 27. Synthesis, kinetic studies and pharmacological evaluation of mutual azo prodrugs of 5-aminosalicylic acid for colon-specific drug delivery in inflammatory bowel disease.
    Dhaneshwar SS; Gairola N; Kandpal M; Vadnerkar G; Bhatt L; Rathi B; Kadam SS
    Eur J Med Chem; 2009 Oct; 44(10):3922-9. PubMed ID: 19442419
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of inflammatory bowel disease. Proceedings of an international symposium on mesalazine. frankfurt, 23-25 March 1988.
    Scand J Gastroenterol Suppl; 1990; 172():1-68. PubMed ID: 2353167
    [No Abstract]   [Full Text] [Related]  

  • 29. [The treatment of inflammatory intestinal diseases with preparations of 5-aminosalicylic acid].
    Frol'kis AV
    Ter Arkh; 1996; 68(2):75-7. PubMed ID: 8771669
    [No Abstract]   [Full Text] [Related]  

  • 30. [Effect of 5-aminosalicylic acid as a constituent of sulfasalazine in the treatment of chronic polyarthritis].
    Wörth WD; Müller W
    Z Rheumatol; 1986; 45(2):79-82. PubMed ID: 2873695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.
    Greenfield SM; Punchard NA; Teare JP; Thompson RP
    Aliment Pharmacol Ther; 1993 Aug; 7(4):369-83. PubMed ID: 8105984
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Sulphasalazine in inflammatory bowel disease: recent advances.
    Cooper BT
    N Z Med J; 1986 Oct; 99(811):757-9. PubMed ID: 2877428
    [No Abstract]   [Full Text] [Related]  

  • 33. Conventional drug therapy in inflammatory bowel disease.
    Griffin MG; Miner PB
    Gastroenterol Clin North Am; 1995 Sep; 24(3):509-21. PubMed ID: 8809233
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inflammatory bowel disease and male infertility: effects of sulfasalazine and 5-aminosalicylic acid on sperm-fertilizing capacity and reactive oxygen species generation.
    Wu FC; Aitken RJ; Ferguson A
    Fertil Steril; 1989 Nov; 52(5):842-5. PubMed ID: 2572460
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Aminosalicylates for the treatment of inflammatory bowel disease.
    Leichtner AM
    J Pediatr Gastroenterol Nutr; 1995 Oct; 21(3):245-52. PubMed ID: 8523207
    [No Abstract]   [Full Text] [Related]  

  • 36. Current drug therapy for inflammatory bowel disease.
    Ogorek CP; Fisher RS
    Compr Ther; 1991 Apr; 17(4):31-7. PubMed ID: 1879116
    [No Abstract]   [Full Text] [Related]  

  • 37. Disposition of mesalazine from mesalazine-delivering drugs in patients with inflammatory bowel disease, with and without diarrhoea.
    Rijk MC; van Schaik A; van Tongeren JH
    Scand J Gastroenterol; 1992 Oct; 27(10):863-8. PubMed ID: 1359629
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Changing treatment of inflammatory bowel diseases].
    Karvonen AL; Matikainen M; Turunen U
    Duodecim; 1994; 110(20):1945-54. PubMed ID: 7555809
    [No Abstract]   [Full Text] [Related]  

  • 39. Tolerability of aminosalicylates in inflammatory bowel disease.
    Ishaq S; Green JR
    BioDrugs; 2001; 15(5):339-49. PubMed ID: 11437696
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inflammatory bowel disease in pediatrics.
    Shapiro JM; Kawatu D; Bancroft B; LeLeiko N
    Med Health R I; 2009 Apr; 92(4):135, 145-7. PubMed ID: 19452758
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.